| | | Human | — | Not specified | Emerging Viral Infections (ZIKV, SARS-CoV-2, and MPXV) and Depression: Ketamine and (S, R)-Ketamine as Promising Antidepressants. |
| | | Human | — | Not specified | Emerging Viral Infections (ZIKV, SARS-CoV-2, and MPXV) and Depression: Ketamine and (S, R)-Ketamine as Promising Antidepressants. |
| | | Human | — | Not specified | Emerging Viral Infections (ZIKV, SARS-CoV-2, and MPXV) and Depression: Ketamine and (S, R)-Ketamine as Promising Antidepressants. |
| | | Human | — | Not specified | Emerging Viral Infections (ZIKV, SARS-CoV-2, and MPXV) and Depression: Ketamine and (S, R)-Ketamine as Promising Antidepressants. |
| | | Human | — | Not specified | Emerging Viral Infections (ZIKV, SARS-CoV-2, and MPXV) and Depression: Ketamine and (S, R)-Ketamine as Promising Antidepressants. |
| | | Human | veterans with comorbid TBI and severe OSA | Not specified | Impact of Medical Comorbidities on Ketamine and Esketamine Treatment Effectiveness for Posttraumatic Stress Disorder and Depression: A Clinical Outcomes Analysis from the VA San Diego Healthcare System. |
| | | Human | veterans | Not specified | Impact of Medical Comorbidities on Ketamine and Esketamine Treatment Effectiveness for Posttraumatic Stress Disorder and Depression: A Clinical Outcomes Analysis from the VA San Diego Healthcare System. |
| | | Human | patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder | Not specified | Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. |
| | | Human | patients with TRD with complex representations | Not specified | Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. |
| | | Human | patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder | Not specified | Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. |
| | | Human | persons diagnosed with MDD or TRD | Not specified | The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review. |
| | | Human | patients with cancer pain and significant depression | Not specified | Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. |
| | | Human | — | Not specified | Prediction of individual treatment allocation between electroconvulsive therapy or ketamine using the Personalized Advantage Index. |
| | | Human | — | Not specified | Licit use of illicit drugs for treating depression: the pill and the process. |
| | | HumanMolecular | — | Not specified | Ketamine, benzoate, and sarcosine for treating depression. |
| | | Animal | patients with treatment-resistant depression | Not specified (intraperitoneal administration). | Antidepressant-like effects of tomatidine and tomatine, steroidal alkaloids from unripe tomatoes, via activation of mTORC1 in the medial prefrontal cortex in lipopolysaccharide-induced depression model mice. |
| | | Human | patients with terminal illness | Not specified | Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. |
| | | Human | — | Not specified | Ketamine Therapy in Complex Cases: A Cautionary Tale of Exacerbated Personality Traits and the Crucial Role of Comprehensive Follow-Up and Psychosocial Interventions. |
| | | Human | help-seeking individuals | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | help-seeking individuals | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | older males | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | help-seeking individuals | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | help-seeking individuals | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | younger females | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | help-seeking individuals | Not specified | Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. |
| | | Human | — | Not specified | Ketamine: An emerging agent in the management of neuropsychiatric disorders. |
| | | Human | patients with Major Depressive Disorder (MDD) | Not specified | The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. |
| | | Human | patients with Major Depressive Disorder (MDD) | Not specified | The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. |
| | | Human | patients with Major Depressive Disorder (MDD) | Not specified | The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. |
| | | Human | people with unipolar major depressive disorder | Not specified | Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. |
| | | Human | people with bipolar disorder experiencing an acute bipolar depressive episode | Not specified | Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. |
| | | Human | people with bipolar disorder experiencing an acute bipolar depressive episode | Not specified | Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. |
| | | Human | patients with major depressive disorder | Not specified in the abstract. | Comparative Efficacy and Safety of Ketamine Versus Electroconvulsive Therapy in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. |
| | | Human | — | Not Assessed | Ketamine in insulin resistance: Pharmacokinetics, cardiovascular implications and cellular effects on cardiomyocytes. |
| | | Human | — | Not specified | Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends. |
| | | Human | — | Low-dose mentioned (specific amount not provided). | Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review. |
| | | Human | pregnant women | Doses less than 0.5 mg were noted as significantly effective. | Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis. |
| | | Human | — | Not specified | PROPHYLACTIC KETAMINE: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS. |
| | | Human | adults | Not available | Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. |
| | | Human | — | Not specified | Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. |
| | | Human | patients with severe cases of treatment-resistant depression | Not mentioned | Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians. |
| | | Human | — | Not mentioned | Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians. |
| | | Human | patients with treatment refractory depression | Not specified | Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. |
| | | Human | — | Not specified | Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. |
| | | Human | patients with treatment-resistant depression | Not specified (plasma concentrations measured, not administered). | D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. |
| | | Human | individuals with treatment-resistant depression | Not specified | Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money. |
| | | Human | patients with treatment-resistant depression | Not specified (repeated intravenous ketamine). | Glutamate plus glutamine to GABA ratio as a predictor of ketamine response in treatment-resistant depression: A double-blind, randomized, open-label extension study. |
| | | Animal | individuals with treatment-resistant depression | 10 mg/kg ketamine | Sex specific effects of ketamine, but not other glutamate receptor modulators, on ethanol self-administration and reinstatement of ethanol seeking in rats. |
| | | Human | patients with treatment-resistant depression | 0.5 mg/kg and 0.2 mg/kg ketamine | Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression. |
| | | Human | — | Not specified | New Pharmacologic Approaches to the Treatment of Bipolar Depression. |
| | | Human | a patient with co-occurring BPD and depression | Not specified | Ketamine-Assisted Psychotherapy for Treatment of Co-occurring Borderline Personality Disorder and Depression: A Case Study. |
| | | Human | 133 adults with treatment-resistant depression (TRD) | Single-dose infusion of 0.5 mg/kg ketamine. | Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. |
| | | Human | 133 adults with treatment-resistant depression (TRD) | Single-dose infusion of 0.5 mg/kg ketamine. | Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. |
| | | Human | participants with lower BMI (BMI < 25) | Single-dose infusion of 0.5 mg/kg ketamine. | Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. |
| | | Human | individuals with low BMI | Single-dose infusion of 0.5 mg/kg ketamine. | Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. |
